Covid-19 Facts & Figures: Omicron still spreading but economic damage is likely to prove limited

In Short

The spread of the Omicron variant refuelled global infection, lifting global daily cases above 3 million for the first time. Advanced economies are now the most affected, with daily infections as high as 3 to 5 times the levels reached at the peak of previous waves.


  • The Omicron variant is spreading fast, with advanced economies currently most affected. It has lifted global daily infections above 3 million for the first time. The World Health Organization predicted that more than half of Eu-rope’s population will be infected with the Omicron variant within the next six to eight weeks.
  • Increasing medical evidence shows that Omicron is much more infectious due to a mutated spike protein but seems to cause less severe illness than delta.
  • As of January 18: 3 million 7-day average new cases, increasing from 2.6 million a week ago and 651,000 a month ago. Now confirmed 334 million cases worldwide. 5.55 million people have died (1.7% of cases) and 269 million have recovered (80.5%).
  • Europe: 110m cases; 7-day average growth of 1.25m vs 1.18m a week ago and 365k a month ago. USA: 67m cases; 7-day average growth of 754k vs 747k a week ago and 130k a month ago.
  • In response to the new wave, Europe has reacted most strongly in tightening restrictions, also causing several protests around the continent. China’s zero tolerance policy is increasingly questioned as disproportionate against new variant characteristics.
  • Europe and US are ramping up booster efforts, with UK most advanced. Vaccines still seem effective in preventing severe disease/deaths, while only booster shots seem to help contain infections. The WHO said repeating booster doses of the original Covid-19 vaccines is not a viable strategy against emerging variants.
  • Vaccines: around 9.75 billion doses have been administered globally, of which 529 million in the USA and 1.16 billion in Europe. 137 vaccines are in clinical evaluation and 194 vaccines are in preclinical evaluation. Globally, 878 million booster doses have already been administered, of which 80 million in the USA and 225 million in Europe.
  • We assume that Omicron will facilitate a shift from a pandemic to an endemic situation. The key risk lies in new variants making the virus more lethal again – a thin tail risk in our view considering the progress in the vaccination campaign and the new drugs for treating Covid-19. Omicron is causing another speed bump in Q1, but the eco-nomic damage is likely to prove more limited than from earlier waves.
  • The zero-Covid policy in Asia is likely to delay the normalisation of the global supply chain and fan near-term inflation pressure. The market focus has rightly shifted from Covid to central banks, with the increasingly hawkish Fed likely to keep the pressure on bond yields and financial volatility.

Download the full publication below

COVID-19 UPDATE Facts & Figures: Omicron still spreading but economic damage is likely to prove limited

© Generali Investments, all rights reserved. This website is provided by Generali Investments Luxembourg S.A. (Generali Investments) and is considered as a marketing communication and financial promotion related its products and services. This website may contain information related to the activity of the following companies: Generali Asset Management S.p.A. Società di gestione del risparmio, Infranity, Sycomore Asset Management, Aperture Investors LLC (including Aperture Investors UK Ltd), Plenisfer Investments S.p.A. Società di gestione del risparmio, Lumyna Investments Limited, Sosteneo S.p.A. Società di gestione del risparmio, Generali Real Estate S.p.A. Società di gestione del risparmio, Conning* and among its subsidiaries Global Evolution Asset Management A/S - including Global Evolution USA, LLC and Global Evolution Fund Management Singapore Pte. Ltd - Octagon Credit Investors, LLC, Pearlmark Real Estate, LLC as well as Generali Investments CEE. *Includes Conning, Inc., Conning Asset Management Limited, Conning Asia Pacific Limited, Conning Investment Products, Inc., Goodwin Capital Advisers, Inc. (collectively, “Conning”).